[HTML][HTML] High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma
MO Ali, S Al Hadidi - Transplantation and Cellular Therapy, 2022 - Elsevier
The use of autologous stem cell transplantation (ASCT) in multiple myeloma (MM) is the
standard of care in patients who are deemed transplantation eligible. Novel therapies …
standard of care in patients who are deemed transplantation eligible. Novel therapies …
Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
C Gillich, D Akhoundova, M Hayoz, Y Aebi… - Cancers, 2023 - mdpi.com
Simple Summary Treatment consolidation using high-dose chemotherapy (HDCT) and
autologous stem cell transplantation (ASCT) has relevantly contributed to achieving durable …
autologous stem cell transplantation (ASCT) has relevantly contributed to achieving durable …
Impact of melphalan day-1 vs day-2 on outcomes after autologous stem cell transplant for multiple myeloma
A Merino, R Shanley, F Rashid, J Langer… - Frontiers in …, 2024 - frontiersin.org
Background Melphalan is the most common conditioning regimen used prior to autologous
stem cell transplant (ASCT); however, there are varying data on optimal melphalan timing …
stem cell transplant (ASCT); however, there are varying data on optimal melphalan timing …
[HTML][HTML] 多发性骨髓瘤自体干细胞移植预处理方案进展
何瑜， 罗云 - Advances in Clinical Medicine, 2023 - hanspub.org
多发性骨髓瘤是血液系统第二大恶性肿瘤, 新药来临之后多发性骨髓瘤患者治疗效果较好,
但终面临复发风险. 对于符合移植条件的患者来说自体干细胞移植仍是主要治疗方案 …
但终面临复发风险. 对于符合移植条件的患者来说自体干细胞移植仍是主要治疗方案 …